Index S&P 500 P/E - EPS (ttm) -8.06 Insider Own 8.54% Shs Outstand 391.00M Perf Week -5.28%
Market Cap 15.83B Forward P/E - EPS next Y -6.69 Insider Trans -0.07% Shs Float 357.38M Perf Month 19.71%
Enterprise Value 12.06B PEG - EPS next Q -2.54 Inst Own 70.24% Short Float 20.01% Perf Quarter 63.61%
Income -3.12B P/S 7.09 EPS this Y 15.58% Inst Trans -4.04% Short Ratio 6.16 Perf Half Y 57.87%
Sales 2.23B P/B 1.70 EPS next Y 14.59% ROA -22.31% Short Interest 71.51M Perf YTD 37.37%
Book/sh 23.86 P/C 3.51 EPS next 5Y 20.28% ROE -29.32% 52W High 55.20 -26.61% Perf Year 30.97%
Cash/sh 11.53 P/FCF - EPS past 3/5Y - -42.94% ROIC -31.11% 52W Low 22.28 81.82% Perf 3Y -76.07%
Dividend Est. - EV/EBITDA - Sales past 3/5Y -43.99% 121.86% Gross Margin 38.93% Volatility 7.90% 8.14% Perf 5Y -77.92%
Dividend TTM - EV/Sales 5.40 EPS Y/Y TTM -38.95% Oper. Margin -155.15% ATR (14) 3.19 Perf 10Y -
Dividend Ex-Date - Quick Ratio 3.73 Sales Y/Y TTM -56.00% Profit Margin -139.61% RSI (14) 49.36 Recom 2.96
Dividend Gr. 3/5Y - - Current Ratio 3.93 EPS Q/Q -1673.01% SMA20 -7.79% Beta 1.34 Target Price 37.63
Payout - Debt/Eq 0.08 Sales Q/Q -45.44% SMA50 12.34% Rel Volume 1.29 Prev Close 41.99
Employees 5800 LT Debt/Eq 0.07 Earnings Feb 13 BMO SMA200 38.65% Avg Volume 11.61M Price 40.51
IPO Dec 07, 2018 Option/Short Yes / Yes EPS/Sales Surpr. 72.79% 10.33% Trades
Volume 14,881,712 Change -3.54%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-28-26 Resumed Barclays
Equal Weight
$25
Jan-07-26 Resumed UBS
Neutral
$34
Dec-12-25 Initiated Jefferies
Hold
$30
Mar-13-25 Initiated Citigroup
Neutral
$40
Feb-18-25 Downgrade Barclays
Overweight → Equal Weight
$111 → $45
Jan-29-25 Downgrade Goldman
Buy → Neutral
$99 → $51
Dec-18-24 Downgrade Argus
Buy → Hold
Dec-10-24 Resumed BofA Securities
Underperform
$41
Nov-19-24 Initiated Berenberg
Hold
$42
Nov-18-24 Upgrade HSBC Securities
Hold → Buy
$58
Nov-15-24 Initiated Wolfe Research
Underperform
$40
Oct-17-24 Initiated Bernstein
Mkt Perform
$55
Sep-13-24 Downgrade Oppenheimer
Outperform → Perform
Sep-13-24 Downgrade JP Morgan
Neutral → Underweight
$88 → $70
Sep-13-24 Downgrade Jefferies
Buy → Hold
$120 → $65
Aug-28-24 Upgrade HSBC Securities
Reduce → Hold
$82
Aug-07-24 Upgrade Deutsche Bank
Sell → Hold
$85 → $80
Aug-05-24 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$125 → $90
Feb-26-24 Downgrade HSBC Securities
Hold → Reduce
$75 → $86
Jan-02-24 Upgrade Oppenheimer
Perform → Outperform
$142
Show Previous Ratings
Today 08:11AM
06:40AM
03:09AM
(The Wall Street Journal)
Feb-11-26 10:01PM
09:23PM
(The Wall Street Journal)
07:28PM
Loading…
07:28PM
06:20PM
(The Wall Street Journal)
04:45PM
04:36PM
04:36PM
04:35PM
04:05PM
(Investor's Business Daily)
03:13PM
02:57PM
01:33PM
(Pharmaceutical Technology)
01:00PM
Loading…
01:00PM
12:29PM
12:27PM
(The Wall Street Journal)
11:46AM
(Pharmaceutical Technology)
10:45AM
10:44AM
10:00AM
(The Wall Street Journal)
09:44AM
08:24AM
08:11AM
07:05AM
06:44AM
06:18AM
06:18AM
06:01AM
05:37AM
Loading…
05:37AM
05:21AM
04:33AM
03:38AM
(The Wall Street Journal)
01:49AM
Feb-10-26 11:24PM
(Associated Press Finance)
07:14PM
(The Wall Street Journal)
06:04PM
(Investor's Business Daily)
05:02PM
05:02PM
02:03PM
12:26PM
11:01AM
10:45AM
08:15AM
07:00AM
06:41AM
Feb-09-26 05:45PM
04:54PM
04:08PM
01:28PM
11:38AM
11:30AM
10:22AM
08:09AM
07:51AM
Feb-06-26 07:00PM
04:31PM
12:33PM
10:10AM
10:10AM
10:00AM
09:00AM
08:23AM
Feb-05-26 09:29AM
08:31AM
Feb-04-26 04:49PM
01:40PM
07:27AM
Feb-03-26 05:10PM
10:37AM
08:55AM
08:30AM
07:56AM
Feb-02-26 05:50PM
Jan-30-26 08:47AM
07:30AM
Jan-29-26 12:42PM
08:16AM
05:20AM
Jan-28-26 09:05PM
11:24AM
Jan-27-26 10:50AM
08:55AM
Jan-26-26 05:50PM
11:15AM
07:00AM
Jan-25-26 09:01AM
Jan-24-26 07:00AM
Jan-23-26 01:55PM
11:10AM
(Investor's Business Daily)
Jan-22-26 05:53PM
05:02PM
04:09PM
02:31PM
02:08PM
12:27PM
11:39AM
10:51AM
09:31AM
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
AFEYAN NOUBAR Director Dec 11 '25 Option Exercise 10.90 23,853 259,998 27,777 Dec 15 09:00 AM AFEYAN NOUBAR Director Dec 11 '25 Sale 29.48 23,853 703,306 3,924 Dec 15 09:00 AM Bancel Stephane Chief Executive Officer Dec 11 '25 Option Exercise 10.90 688,073 7,499,996 6,181,970 Dec 15 08:59 AM Flagship Pioneering Inc. Affiliate Dec 11 '25 Proposed Sale 29.49 23,853 703,306 Dec 11 04:30 PM Hussain Abbas Director Dec 09 '25 Sale 27.60 504 13,910 1,515 Dec 11 04:16 PM Hussain Abbas Director Dec 09 '25 Proposed Sale 27.60 504 13,910 Dec 09 10:26 AM Hussain Abbas Director Jun 11 '25 Sale 28.00 312 8,736 580 Jun 12 04:22 PM Hussain Abbas Director Jun 11 '25 Proposed Sale 28.00 312 8,736 Jun 11 10:06 AM Bancel Stephane Chief Executive Officer Mar 03 '25 Buy 31.22 160,314 5,004,318 9,210,686 Mar 04 04:27 PM SAGAN PAUL Director Mar 03 '25 Buy 31.76 31,620 1,004,251 312,027 Mar 04 04:24 PM
